Edwards Lifesciences Corp. (EW) Tops Q2 EPS by 11c; Boosts Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Edwards Lifesciences (EW) PT Lifted to $100 at Jefferies Amid Strong Q2
July 30, 2014 6:54 AM EDTJefferies analyst Raj Denhoy reiterated a Buy rating and boosted his price target on Edwards Lifesciences (NYSE: EW) to $100.00 (from $94.00) following strong Q2 results and outlook.
Denhoy comments, "EW posted a high-quality 2Q: (1) US Sapien exceeded estimates despite late XT approval and ongoing... More
